P210 - SARCOPENIC OBESITY PREVALENCE USING TWO DIFFERENT METHODS

P210

SARCOPENIC OBESITY PREVALENCE USING TWO DIFFERENT METHODS

M. M. Pires¹, L. Cristino¹, I. Rego De Figueiredo^1,*, F. Simas¹, J. Silva-Nunes¹, L. Manaças¹

¹Centro de Tratamento Cirúrgico de Obesidade, Hospital Curry Cabral, Unidade Local de Saúde São José, Centro Clínico Académico de Lisboa, Lisboa, Portugal

Rationale: Sarcopenic obesity is a relevant condition due to its increased morbidity and mortality. In 2022, new guidelines were defined by ESPEN/EASO. We aimed to assess the prevalence in a group of patients followed in our multidisciplinary bariatric clinic.

Methods: A cross-section study was performed in patients with obesity. SARC-F was applied as the screening tool. Sarcopenia was assessed by both the Skeletal Muscle Mass (SMI) and the Fat Free Mass Index (FFMI). Muscle function was measured by handgrip strength. Analytical data on total protein serum level was also collected.

Results: A total of 65 patients were included, with a female predominance (85%). The most frequent comorbidities were osteoarticular disease (48%), hypertension (46%) and venous insufficiency (45%).

Mean BMI was 44±5,8 kg/m2, with a mean fat mass percentage of 46,5±7,3%, and a waist circumference of 126±14,7cm.

FFM was on average 61.9±17kgs, which resulted in 0 patients having sarcopenia using the FFMI and 2 with the SMI. Nevertheless, 29,6% of the patients were at risk according to the SARC-F screening tool. The handgrip functional assessment showed lower strength on compared to the expected (86% at right and 82% on the left).

Conclusion: Only a small number of patients fulfilled the formal criteria for sarcopenic obesity, and only according to one of the indexes used. However, muscle function was already compromised in a significant number of patients, with up to one third of them at risk.

Disclosure of Interest: None declared